Shots:
- Bio-Thera & STADA have expanded their partnership to BAT1806, a biosimilar version of Roche’s RoActemra (tocilizumab), whose 20mg/ml vial formulation received EMA’s approval in Jun 2024 for several arthritic conditions
- As per the deal, STADA will obtain exclusive rights to commercialize BAT1806 in the EU, UK, Switzerland & select other countries under its own marketing authorization while Bio-Thera will develop, manufacture, & supply BAT1806
- Collaboration expanded on Bio-Thera & STADA’s 2024 deal, which granted STADA exclusive regulatory & commercial rights to BAT2506 (Biosimilar, Simponi; MAA under EMA’s review) in mentioned regions, while Bio-Thera handled its development, manufacturing, & supply
Ref: STADA| Image: Bio-Thera & STADA | Press Release
Related News:- Bio-Thera Reports the US FDA’s BLA Acceptance of BAT2506 (Biosimilar, Simponi)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
